DK1121431T5 - Ikke-endogene, konstitutivt aktiverede humane G-protein-bundne receptorer - Google Patents

Ikke-endogene, konstitutivt aktiverede humane G-protein-bundne receptorer

Info

Publication number
DK1121431T5
DK1121431T5 DK99951991T DK99951991T DK1121431T5 DK 1121431 T5 DK1121431 T5 DK 1121431T5 DK 99951991 T DK99951991 T DK 99951991T DK 99951991 T DK99951991 T DK 99951991T DK 1121431 T5 DK1121431 T5 DK 1121431T5
Authority
DK
Denmark
Prior art keywords
endogenous
sub
sup
codon
gpcr
Prior art date
Application number
DK99951991T
Other languages
Danish (da)
English (en)
Other versions
DK1121431T3 (da
Inventor
Dominic P Behan
Derek T Chalmers
Chen W Liaw
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of DK1121431T3 publication Critical patent/DK1121431T3/da
Application granted granted Critical
Publication of DK1121431T5 publication Critical patent/DK1121431T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK99951991T 1998-10-13 1999-10-12 Ikke-endogene, konstitutivt aktiverede humane G-protein-bundne receptorer DK1121431T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/170,496 US6555339B1 (en) 1997-04-14 1998-10-13 Non-endogenous, constitutively activated human protein-coupled receptors
PCT/US1999/023938 WO2000022129A1 (en) 1998-10-13 1999-10-12 Non-endogenous, constitutively activated human g protein-coupled receptors

Publications (2)

Publication Number Publication Date
DK1121431T3 DK1121431T3 (da) 2006-06-26
DK1121431T5 true DK1121431T5 (da) 2008-03-03

Family

ID=22620080

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99951991T DK1121431T5 (da) 1998-10-13 1999-10-12 Ikke-endogene, konstitutivt aktiverede humane G-protein-bundne receptorer

Country Status (14)

Country Link
US (2) US6555339B1 (https=)
EP (1) EP1121431B9 (https=)
JP (2) JP4672866B2 (https=)
KR (1) KR100598752B1 (https=)
CN (1) CN1329511C (https=)
AT (1) ATE318311T1 (https=)
AU (5) AU769987B2 (https=)
CA (1) CA2342314A1 (https=)
DE (3) DE1121431T1 (https=)
DK (1) DK1121431T5 (https=)
ES (1) ES2163384T3 (https=)
IL (2) IL141965A0 (https=)
NZ (1) NZ510331A (https=)
WO (2) WO2000021987A2 (https=)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
DK1584683T3 (da) * 1998-11-20 2007-10-29 Arena Pharm Inc Human G-protein-koblet orphan receptor RUP3
US7816492B2 (en) * 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
GB9903767D0 (en) * 1999-02-18 1999-04-14 Univ Glasgow Receptor assay
AU6385200A (en) * 1999-07-30 2001-02-19 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for prognostication, diagnosis, prevention, and treatment of bone-related disorders and other disorders
JP4768946B2 (ja) * 1999-11-17 2011-09-07 アリーナ ファーマシューティカルズ， インコーポレイテッド ヒトｇタンパク質共役型受容体の内因性および非内因性型
WO2001048483A2 (en) * 1999-12-10 2001-07-05 Astrazeneca Ab Method for screening of appetite control agents
EP1265922A2 (en) * 1999-12-17 2002-12-18 AstraZeneca AB Agonists and antagonists of the receptor gpr19 and their use in appetite control
GB0003898D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
GB0003902D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
EP1255779A2 (en) * 2000-02-18 2002-11-13 Glaxo Group Limited Identification of modulators of gpr41 or gpr42 activity
AU2001241778A1 (en) * 2000-02-29 2001-09-12 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of cardiovascular, hepatic, and bone disease
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1149907A1 (en) * 2000-04-26 2001-10-31 Aventis Pharma Deutschland GmbH EDG8 receptor, its preparation and use
NZ522215A (en) 2000-04-26 2004-05-28 Aventis Pharma Gmbh EDG8 receptor, its preparation and use
EP1297127A2 (en) * 2000-05-03 2003-04-02 AstraZeneca AB Gpr22 modulators as appetite-control agents
AU2001274522A1 (en) * 2000-06-15 2001-12-24 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor protein and dna thereof
WO2001098351A2 (en) * 2000-06-16 2001-12-27 Incyte Genomics, Inc. G-protein coupled receptors
DE60139399D1 (de) 2000-06-21 2009-09-10 Takeda Pharmaceutical Gpr8 ligand und dafuer kodierende dna
US20040086940A1 (en) * 2000-07-04 2004-05-06 Sachio Shibata Novel g protein-coupled receptor protein and dna thereof
WO2002013845A2 (en) * 2000-08-18 2002-02-21 Novartis Ag Inflammation related g-protein coupled receptor
WO2002018590A2 (en) * 2000-08-30 2002-03-07 John Hopkins University School Of Medicine Identification of activated receptors and ion channels
WO2001027632A2 (en) * 2000-10-02 2001-04-19 Biofocus Discovery Limited Cellular receptor mutations predicted by multiple-sequence-allignment
EP1344823A4 (en) * 2000-11-30 2005-03-16 Takeda Chemical Industries Ltd NEW G-PROTEIN-COUPLED RECEPTOR PROTEINS AND THEIR DNAS
US7241579B2 (en) 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
CN1516706A (zh) * 2001-02-26 2004-07-28 阿伦纳药品公司 人g蛋白偶联受体的内源性和非内源性形式
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US6919176B2 (en) * 2001-05-07 2005-07-19 Amgen Inc. Polypeptides and nucleic acids associated with cancer
US7247440B2 (en) 2001-05-15 2007-07-24 Takeda Pharmaceutical Company Limited Method of screening preventives or remedies for obesity
US20020177190A1 (en) * 2001-05-24 2002-11-28 Yanbin Liang Recombinant simian GPR3 receptor
WO2002100882A2 (en) * 2001-06-05 2002-12-19 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated versions of plant g protein-coupled receptor: gcr1
JP2003018992A (ja) * 2001-06-28 2003-01-21 Inst Of Physical & Chemical Res Ｐａｅｌ受容体、Ｐａｅｌ受容体発現細胞および動物、ならびにパーキンソン病治療薬のスクリーニング法
JP2004533847A (ja) * 2001-07-13 2004-11-11 アクゾ・ノベル・エヌ・ベー Ｇｐｒ５０の対立遺伝子変異体
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
US20030119742A1 (en) * 2001-11-05 2003-06-26 Millennium Pharmaceuticals, Inc. Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587,10183, 10550, 12680, 17921, 32248, 60489 or 93804
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
JP4360915B2 (ja) 2002-01-07 2009-11-11 ユーロスクリーン・ソシエテ・アノニム Ｇタンパク質共役受容体ｇｐｒ４３のリガンドおよびその使用
EP1336655A1 (en) * 2002-01-12 2003-08-20 Aventis Pharma Deutschland GmbH Method of identifying protein CAMS (constitutively active mutants)
WO2003062396A2 (en) * 2002-01-23 2003-07-31 Arena Pharmaceuticals, Inc. Non-endogenous versions of human g protein-coupled receptor: fshr
US20060057648A1 (en) * 2002-02-06 2006-03-16 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
EP1479768B1 (en) 2002-02-14 2010-04-28 Takeda Pharmaceutical Company Limited Novel screening method
WO2003078602A2 (en) * 2002-03-15 2003-09-25 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
AU2003241037A1 (en) * 2002-06-08 2003-12-22 Astrazeneca Ab Methods for the detection of polymorphisms in human gpr50
CN100473662C (zh) * 2002-08-01 2009-04-01 阿瑞那制药公司 治疗缺血性心脏病及充血性心衰竭的人类g蛋白偶联受体及其调节物
WO2004015427A2 (en) * 2002-08-06 2004-02-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
WO2004015426A1 (en) * 2002-08-06 2004-02-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
US20060239999A1 (en) * 2002-08-22 2006-10-26 Mayumi Saki Preventive and/or therapeutic drugs for asthma
WO2004038407A2 (en) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
US7056685B1 (en) * 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
CN101134757A (zh) 2002-11-06 2008-03-05 安姆根有限公司 稠合杂环化合物
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
AU2003297644A1 (en) * 2002-12-04 2004-06-23 Synaptic Pharmaceutical Corporation Uses of the snorf55 receptor
US20040157253A1 (en) * 2003-02-07 2004-08-12 Millennium Pharmaceuticals, Inc. Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
WO2004083394A2 (en) * 2003-03-18 2004-09-30 Arena Pharmaceuticals Inc. Human g protein-coupled receptors and modulators thereof for the treatment of inflammatory disorders
WO2004093912A1 (ja) * 2003-04-23 2004-11-04 Kyowa Hakko Kogyo Co. Ltd. 好中球性炎症疾患の予防および／または治療剤
US20080009551A1 (en) * 2003-04-30 2008-01-10 Arena Pharmaceuticals, Inc. Methods and Compositions for Identifying Modulators of G Protein-Coupled Receptors
ATE500270T1 (de) * 2003-05-20 2011-03-15 Univ Glasgow Materialien und methoden die sich auf g-protein gekoppelte rezeptor oligomere beziehen
ATE405827T1 (de) * 2003-09-11 2008-09-15 Takeda Pharmaceutical Screening-verfahren
EP1677778A2 (en) * 2003-10-09 2006-07-12 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
WO2005040829A2 (en) * 2003-10-21 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2005040211A2 (en) * 2003-10-23 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005040828A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005040825A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2005074980A1 (en) * 2004-01-29 2005-08-18 Cellzome Ag Treatment of neurodegenerative diseases by the use of gpr49
CN1929833A (zh) 2004-02-20 2007-03-14 安万特药物公司 Hm74的氧杂十氢萘调节剂
WO2005101005A1 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 32 (gpr32)
DE602005024537D1 (de) * 2004-04-27 2010-12-16 Takeda Pharmaceutical Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
GB0508988D0 (en) 2005-05-03 2005-06-08 Novartis Ag Organic compounds
US8429755B2 (en) 2005-05-26 2013-04-23 Sandisk Technologies Inc. System and method for receiving digital content
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
CN101287832A (zh) * 2005-10-14 2008-10-15 艾尼纳制药公司 Gpr22和其相关方法
CN101304654A (zh) * 2005-11-10 2008-11-12 艾尼纳制药公司 用于治疗肥胖和其相关症状的人类g蛋白-偶合受体和其调节剂
GB2456236B8 (en) 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable muscarinic receptor mutants
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
WO2010091692A2 (en) * 2009-04-30 2010-08-19 H. Lundbeck A/S Constitutively active mutants and uses thereof
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5804341B2 (ja) * 2010-08-06 2015-11-04 国立大学法人山口大学 エストロゲン関連疾患の判定方法
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
BR112014009050B1 (pt) 2011-10-14 2022-06-21 Medimmune Limited Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
HRP20182129T1 (hr) 2012-10-12 2019-02-08 Adc Therapeutics Sa Konjugati protutijelo - pirolobenzodiazepin
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
RS57694B1 (sr) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pirolobenzodiazepin - anti-psma konjugati antitela
JP6392765B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
CN110627797A (zh) 2012-12-21 2019-12-31 麦迪穆有限责任公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
CN105189507A (zh) 2012-12-21 2015-12-23 斯皮罗根有限公司 吡咯并苯并二氮杂卓及其结合物
TWI680766B (zh) 2013-03-13 2020-01-01 英商梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
AU2014229529B2 (en) 2013-03-13 2018-02-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
JP6671292B2 (ja) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
EP3082876B1 (en) 2013-12-16 2018-01-17 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CA2945706C (en) * 2014-04-25 2023-10-24 Libramen Naturals Inc. G-protein coupled receptor 22 transformed cell lines and uses therefor
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
CN107073136A (zh) 2014-09-17 2017-08-18 健泰科生物技术公司 吡咯并苯并二氮杂卓及其抗体二硫化物偶联物
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
AU2015358532C1 (en) 2014-12-03 2020-10-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CR20180243A (es) 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
EP3365025B1 (en) 2015-10-20 2020-07-15 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017140803A1 (en) 2016-02-16 2017-08-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
WO2017140793A1 (en) 2016-02-16 2017-08-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of ccr9 for treating tumor resistance to immune responses
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CN110582505B (zh) 2017-04-18 2021-04-02 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CA3064804A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
KR102270107B1 (ko) 2017-08-18 2021-06-30 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
EP3684773B1 (en) 2017-09-20 2026-04-29 pH Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP7241161B2 (ja) 2018-08-01 2023-03-16 イミュニティーバイオ、インコーポレイテッド 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP7708662B2 (ja) 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN114848822A (zh) * 2022-06-01 2022-08-05 合肥工业大学 Gpr31抑制剂在制备预防和治疗血管钙化药物中的应用
WO2024044659A1 (en) * 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Constitutively active g protein-coupled receptor compositions and methods of use thereof
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
KR20260012304A (ko) 2023-04-17 2026-01-26 피크 바이오, 인크. 항체 및 항체-약물 접합체 및 사용 방법 및 합성 공정 및 중간체
WO2025207642A1 (en) * 2024-03-25 2025-10-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Cxcr3 isoforms to improve recombinant receptor trafficking
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7492291A (en) 1990-02-26 1991-09-18 Board Of Trustees Of The Leland Stanford Junior University Identification and expression of insect steroid receptor dna sequences
EP0668930B1 (en) 1991-10-01 2002-12-18 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES A method of identifying ligands and antagonists of ligands
EP0745121B1 (en) * 1992-05-14 2007-06-20 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
EP1063292A3 (en) 1992-09-25 2001-04-25 Synaptic Pharmaceutical Corporation DNA encoding human alpha 1 adrenergic receptors and uses thereof
EP0612845A3 (en) 1993-02-26 1994-09-21 American Cyanamid Co Purified opioid receptor.
AU1173995A (en) 1993-11-10 1995-05-29 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
EP0737314A4 (en) * 1993-12-30 1999-11-03 Salk Inst For Biological Studi USES FOR GAL 4 RECEPTOR CONSTRUCTS
US5573944A (en) 1994-07-22 1996-11-12 President And Fellows Of Harvard College Yeast cell expressing heterologous receptor kinase
AU4426296A (en) 1994-08-11 1996-03-07 Takeda Chemical Industries Ltd. G protein coupled receptor protein, production, and use thereof
CA2135253A1 (en) 1994-11-07 1996-05-08 Michael Dennis Compound screening based on a window of chemical-messenger-independent activity
WO1996039442A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. G-protein receptor htnad29
EP0862614A1 (en) 1995-09-20 1998-09-09 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein
FR2742033B1 (fr) * 1995-12-08 1998-01-16 Achart Jacques Appareil pour l'ouverture de coquillages de mollusques bivalves
JP4442930B2 (ja) 1995-12-11 2010-03-31 タフツ メディカル センター インコーポレイテッド ペプチドホルモンレセプターリガンドに関するアッセイ法およびその使用
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
AU3648297A (en) 1996-07-02 1998-01-21 President And Fellows Of Harvard College Receptor tyrosine phosphatase, and uses related thereto
AU733007B2 (en) * 1996-09-24 2001-05-03 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
EP0948529A4 (en) 1996-12-27 2002-09-25 Merck & Co Inc HUMAN GALANINE RECEPTOR GALR2 AND THE NUCLEIC ACID ENCODING IT.
US6403305B1 (en) 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor
AU6343998A (en) 1997-02-27 1998-09-18 Christina C. Egan Constitutively activated serotonin receptors
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
AU743259B2 (en) 1997-04-14 2002-01-24 Arena Pharmaceuticals, Inc. A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
US5891720A (en) 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
EP0878542A3 (en) 1997-04-22 2000-04-19 Smithkline Beecham Corporation cDNA clone HMTMF81 that encodes a novel human 7-transmembrane receptor
WO1998056820A1 (en) 1997-06-12 1998-12-17 Smithkline Beecham Corporation Hm74a receptor
US5955308A (en) 1997-06-18 1999-09-21 Smithkline Beecham Corporation cDNA clone HEAOD54 that encodes a human 7-transmembrane receptor
US6222029B1 (en) 1997-08-01 2001-04-24 Genset 5′ ESTs for secreted proteins expressed in brain
JP4280886B2 (ja) 1997-11-11 2009-06-17 小野薬品工業株式会社 ヒトリゾホスファチジン酸受容体物質およびその用途
SE9704836D0 (sv) 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
DE69941330D1 (de) 1998-03-26 2009-10-08 Univ R Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region
US6107324A (en) 1998-04-14 2000-08-22 Arena Pharmaceuticals Inc. 5-HT2A receptor inverse agonists
MXPA01001176A (es) * 1998-07-31 2005-07-25 Arena Pharm Inc Receptores huerfanos acoplados a la proteina g constitutivamente activados endogenos.
EP1111049A4 (en) 1998-09-03 2002-10-29 Asahi Chemical Ind New receptor protein and method for diagnosing inflammatory diseases using it
US20030229216A1 (en) * 1998-10-13 2003-12-11 Ruoping Chen Constitutively activated human G protein coupled receptors
KR20010080882A (ko) 1998-10-13 2001-08-25 리처드 피. 버군 쥬니어 구성적으로 활성화된 비내생성 인간 ｇ 단백질 결합형수용체
EP1153932A1 (en) 1999-02-19 2001-11-14 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
JP2003508026A (ja) 1999-07-15 2003-03-04 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ヒトｇ−タンパク質共役型受容体
WO2001007606A1 (en) 1999-07-27 2001-02-01 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
JP2003510027A (ja) 1999-08-17 2003-03-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Ｐｇｐｃｒ−３ポリペプチドおよびそのｄｎａ配列
WO2001014577A1 (en) 1999-08-24 2001-03-01 Smithkline Beecham Corporation Molecular cloning of a galanin like 7tm receptor (axor40)
WO2001016159A1 (en) 1999-08-27 2001-03-08 Smithkline Beecham Corporation Gpcr, theant
GB9923889D0 (en) 1999-10-08 1999-12-08 Pfizer Ltd Novel polypeptide
GB9924951D0 (en) 1999-10-21 1999-12-22 Pfizer Ltd Novel polypeptide
AU1575601A (en) 1999-10-27 2001-05-08 Pharmacia & Upjohn Company G protein-coupled receptors expressed in brain
CA2390547A1 (en) 1999-11-17 2001-05-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors

Also Published As

Publication number Publication date
US6555339B1 (en) 2003-04-29
AU2004203102B2 (en) 2007-10-18
DK1121431T3 (da) 2006-06-26
DE69929993T2 (de) 2006-10-26
WO2000021987A3 (en) 2000-07-13
AU2011200016A1 (en) 2011-01-27
CA2342314A1 (en) 2000-04-20
JP2003531565A (ja) 2003-10-28
ES2163384T3 (es) 2006-12-01
US20030105292A1 (en) 2003-06-05
ATE318311T1 (de) 2006-03-15
AU2004203102A1 (en) 2004-07-29
EP1121431B1 (en) 2006-02-22
US7410777B2 (en) 2008-08-12
ES2163384T1 (es) 2002-02-01
DE1121431T1 (de) 2002-05-23
CN1329511C (zh) 2007-08-01
JP4685241B2 (ja) 2011-05-18
IL141965A (en) 2008-08-07
EP1121431A1 (en) 2001-08-08
JP4672866B2 (ja) 2011-04-20
IL141965A0 (en) 2002-03-10
AU6430799A (en) 2000-05-01
CN1398298A (zh) 2003-02-19
AU2008200231A1 (en) 2008-02-07
WO2000022129A1 (en) 2000-04-20
WO2000021987A2 (en) 2000-04-20
WO2000022129A9 (en) 2000-09-14
KR100598752B1 (ko) 2006-07-11
JP2002527727A (ja) 2002-08-27
DE69929993T4 (de) 2008-08-28
DE69929993D1 (de) 2006-04-27
KR20010085911A (ko) 2001-09-07
AU769987B2 (en) 2004-02-12
WO2000021987A9 (en) 2000-08-24
EP1121431B9 (en) 2007-10-24
HK1038040A1 (en) 2002-03-01
NZ510331A (en) 2004-07-30
AU2011200511A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
DK1121431T5 (da) Ikke-endogene, konstitutivt aktiverede humane G-protein-bundne receptorer
Ulrich et al. Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor
Silver et al. Reconstitution by MHC-restricted peptides of HLA-A2 heavy chain with β2-microglobulin, in vitro
Couvineau et al. Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains
Krapivinsky et al. The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K+-channel proteins
EP1133559B1 (en) Human orphan g protein-coupled receptor rup3
US5883075A (en) Cyclic endothelin antagonists
Biebermann et al. A conserved tyrosine residue (Y601) in transmembrane domain 5 of the human thyrotropin receptor serves as a molecular switch to determine G‐protein coupling
AU2018322482B2 (en) Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (RAGE)
AU1769601A (en) Endogenous and non-endogenous versions of human G protein-coupled receptors
WO1998056820A1 (en) Hm74a receptor
Kaiser et al. G protein preassembly rescues efficacy of W6. 48 toggle mutations in neuropeptide Y2 receptor
US5854216A (en) Marker for growth hormone-releasing factor receptors
Delporte et al. Discovery of a potent atrial natriuretic peptide antagonist for ANPA receptors in the human neuroblastoma NB-OK-1 cell line
JPH10295376A (ja) ヒトｇｐｒ１４レセプターのクローニング
EP0552417A1 (en) Cyclic peptides and use thereof
DK0692026T3 (da) En human T-cellereceptor fra den G-proteinkoblede receptorfamilie
Durek et al. Melanocortin 1 receptor agonists based on a bivalent, bicyclic peptide framework
Maiti et al. GnRH-II analogs for selective activation and inhibition of non-mammalian and type-II mammalian GnRH receptors
ES2283024T3 (es) Un nuevo receptor galanina.
CA2330251A1 (en) Cloning and identification of the motilin receptor
Sridharan et al. Tail wags the dog: activity of krait natriuretic peptide is determined by its C-terminal tail in a natriuretic peptide receptor-independent manner
EP1265926A1 (en) Melanin concentrating hormone receptor chimeric and fusion proteins
Shibasaki et al. Characterization of the carboxyl terminal‐truncated endothelin B receptor coexpressed with G protein‐coupled receptor kinase 2
Shabanpoor et al. Effect of helix-promoting strategies on the biological activity of novel analogues of the B-chain of INSL3